Table 3 The biological and clinical characteristics of the 76 AML patients included in the study
Patient characteristics | |||
|---|---|---|---|
Age | Secondary AML | ||
Median (years) | 67 | Chemotherapy | 5 |
Range (years) | 18–87 | CML blast phase | 1 |
CMML | 4 | ||
Gender | Li-Fraumeni syndrome | 1 | |
Females | 34 | MDS | 6 |
Males | 42 | Polycythemia vera | 1 |
Myelofibrosis | 3 | ||
De novo AML | 51 | ||
AML relapse | 4 | Total | 21 |
Cell morphology | |||
|---|---|---|---|
FAB classification | CD34 expression | ||
M0 | 4 | Negative (<20%) | 19 |
M1 | 16 | Positive (>20%) | 51 |
M2 | 16 | nd | 6 |
M4 | 18 | ||
M5 | 15 | ||
M6 | 1 | ||
M7 | 1 | ||
nd | 5 | ||
Cell genetics | |||
|---|---|---|---|
Cytogenetics a | NPM1 status | ||
Favorable | 8 | Mutated | 24 |
Intermediate | 6 | Wild-type | 39 |
Normal | 38 | nd | 13 |
Adverse | 16 | ||
nd | 8 | FLT3 status | |
ITD | 27 | ||
Wild-type | 35 | ||
nd | 14 |
